NASDAQ:PCYC Pharmacyclics (PCYC) Stock Price, News & Analysis → FW: 234x Gain (From Weiss Ratings) (Ad) Free PCYC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pharmacyclics alerts: Email Address Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Pharmacyclics Stock (NASDAQ:PCYC)Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.Read More Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… PCYC Stock News HeadlinesSeptember 23, 2023 | investing.comPCYC Historical DataMarch 24, 2023 | thestreet.comPharmacyclics (PCYC) Stock Spikes Today Following $21 Billion AbbVie Merger DealMay 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 24, 2023 | thestreet.comPharmacyclics Reaches New 52-Week High (PCYC)January 29, 2023 | thestreet.comPharmacyclics' Imbruvica Extends Survival in Elderly Leukemia PatientsJanuary 13, 2023 | thestreet.comASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)January 2, 2023 | thestreet.comStocks in Motion: PharmacyclicsJune 16, 2022 | streetinsider.comPulnovo Medical Announces Dr. Krishna Sudhir Joins Scientific Advisory Board - StreetInsider.comMay 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. June 15, 2022 | prnewswire.comPulnovo Medical Announces Dr. Krishna Sudhir Joins Scientific Advisory Board - PR NewswireJune 12, 2022 | streetinsider.comNew IMBRUVICA® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia - StreetInsider.comJune 7, 2022 | prnewswire.comCritical Limb Ischemia Market to Progress at a CAGR of 10.6% by 2030 | DelveInsight - PR NewswireJune 6, 2022 | businesswire.comArtiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer - Business WireJune 6, 2022 | benzinga.comGlobal Graft Versus Host Disease (GvHD) Treatment Market Report 2022: Corticosteroids Accounted for More - BenzingaJune 3, 2022 | streetinsider.comCelularity Appoints Industry Leader Diane Parks to its Board of Directors - StreetInsider.comJune 1, 2022 | law360.comRising Star: Covington & Burling's Brianne Bharkhda - Law360April 8, 2022 | thestreet.comReal Story: Cancer Drug ManiaSee More Headlines Receive PCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharmacyclics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:PCYC CUSIP71693310 CIK949699 WebN/A Phone+1-302-6587581FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report PCYC Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Pharmacyclics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmacyclics investors own include Gilead Sciences (GILD), Baidu (BIDU), Regeneron Pharmaceuticals (REGN), Jazz Pharmaceuticals (JAZZ), Netflix (NFLX), Biogen (BIIB), Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS) and (QIHU) (QIHU). This page (NASDAQ:PCYC) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmacyclics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
